These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 20954856)

  • 41. Evaluation of hydroxypropyl methylcellulose matrix systems as swellable gastro-retentive drug delivery systems (GRDDS).
    Matharu AS; Motto MG; Patel MR; Simonelli AP; Dave RH
    J Pharm Sci; 2011 Jan; 100(1):150-63. PubMed ID: 20572054
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of photostable gastro retentive formulation for nifedipine using low-density polypropylene microporous particles.
    Pawar AP; Shelake MR; Bothiraja C; Kamble RN
    J Microencapsul; 2012; 29(5):409-16. PubMed ID: 22295892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymer blends used to prepare nifedipine loaded hollow microspheres for a floating-type oral drug delivery system: in vitro evaluation.
    Zhao L; Wei YM; Yu Y; Zheng WW
    Arch Pharm Res; 2010 Mar; 33(3):443-50. PubMed ID: 20361310
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Deciphering nifedipine in vivo delivery from modified release dosage forms: Identification of food effect.
    Ilić M; Kovačević I; Parojčić J
    Acta Pharm; 2015 Dec; 65(4):427-41. PubMed ID: 26677899
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Preparation and in vitro release characteristics of pulsed-release tablets of Apocynum venetum].
    Yang H; Xie F; Yang Y; Luo Y
    Zhongguo Zhong Yao Za Zhi; 2011 Jun; 36(11):1427-30. PubMed ID: 22779170
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suitability of Gelucire 50/13 for controlled release formulation of salbutamol sulphate.
    Mohsin S; Rahman NU; Idrees MA; Sarfraz MK; Khan MK; Mustafa G
    Pak J Pharm Sci; 2012 Jan; 25(1):35-41. PubMed ID: 22186307
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Denatured Whey Protein Powder as a New Matrix Excipient: Design and Evaluation of Mucoadhesive Tablets for Sustained Drug Release Applications.
    Hsein H; Garrait G; Tamani F; Beyssac E; Hoffart V
    Pharm Res; 2017 Feb; 34(2):365-377. PubMed ID: 28004316
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of binary polymer system in drug release rate modulation. 2. Influence of formulation variables and hydrodynamic conditions on release kinetics.
    Kim H; Fassihi R
    J Pharm Sci; 1997 Mar; 86(3):323-8. PubMed ID: 9050800
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of microenvironment pH of swellable and erodable buffered matrices on the release characteristics of diclofenac sodium.
    Al-Taani BM; Tashtoush BM
    AAPS PharmSciTech; 2003; 4(3):E43. PubMed ID: 14621975
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of novel diclofenac potassium controlled release tablets by wet granulation technique and the effect of co-excipients on in vitro drug release rates.
    Shah S; Khan GM; Jan SU; Shah K; Hussain A; Khan H; Khan H; Khan H; Khan KA
    Pak J Pharm Sci; 2012 Jan; 25(1):161-8. PubMed ID: 22186325
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Factorial analysis of the influence of dissolution medium on drug release from carrageenan-diltiazem complexes.
    Bonferoni MC; Rossi S; Ferrari F; Stavik E; Pena-Romero A; Caramella C
    AAPS PharmSciTech; 2000 Jun; 1(2):E15. PubMed ID: 14727848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro evaluation of theophylline matrices using xyloglucan.
    Badillo N; Ghaly ES
    Pharm Dev Technol; 2008; 13(6):481-6. PubMed ID: 18720251
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design of floating bilayer tablets of diltiazem hydrochloride and lovastatin.
    Kulkarni AS; Bhatia MS
    PDA J Pharm Sci Technol; 2008; 62(5):344-52. PubMed ID: 19055230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An innovative matrix controlling drug delivery produced by thermal treatment of DC tablets containing polycarbophil and ethylcellulose.
    Caviglioli G; Baldassari S; Cirrincione P; Russo E; Parodi B; Gatti P; Drava G
    Int J Pharm; 2013 Dec; 458(1):74-82. PubMed ID: 24144954
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro quantitative ((1))H and ((19))F nuclear magnetic resonance spectroscopy and imaging studies of fluvastatin™ in Lescol® XL tablets in a USP-IV dissolution cell.
    Zhang Q; Gladden L; Avalle P; Mantle M
    J Control Release; 2011 Dec; 156(3):345-54. PubMed ID: 21911016
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative evaluation of drug release from aged prolonged polyethylene oxide tablet matrices: effect of excipient and drug type.
    Shojaee S; Kaialy W; Cumming KI; Nokhodchi A
    Pharm Dev Technol; 2016 Mar; 21(2):189-95. PubMed ID: 25410967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimization of primaquine diphosphate tablet formulation for controlled drug release using the mixture experimental design.
    Duque MD; Kreidel RN; Taqueda ME; Baby AR; Kaneko TM; Velasco MV; Consiglieri VO
    Pharm Dev Technol; 2013; 18(5):1247-54. PubMed ID: 22670808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Formulation and pharmacokinetic evaluation of once-daily sustained-released system of nifedipine with solid dispersion and coating techniques.
    Wei YM; Xue ZK; Wang P; Zhao L
    Arch Pharm Res; 2013 Jul; 36(7):864-73. PubMed ID: 23463334
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of novel spray coated soft elastic gelatin capsule sustained release formulations of nifedipine.
    Abd El-Sattar Fahmy S; Christensen JM; Ayres JW
    Drug Dev Ind Pharm; 2009 Aug; 35(8):1009-21. PubMed ID: 19274589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors affecting the release of nifedipine from a swellable elementary osmotic pump.
    Nokhodchi A; Momin MN; Shokri J; Shahsavari M; Rashidi PA
    Drug Deliv; 2008 Jan; 15(1):43-8. PubMed ID: 18197523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.